Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR^WT and EGFR^T790M

References

• Jang J, To C, De Clercq DJ, et al. Mutant‐selective allosteric EGFR degraders are effective against a broad range of drug‐resistant mutations. Angew. Chem 2020;132:14589–97.
   Google Scholar
• Visconti R, Morra F, Guggino G, Celetti A. The between now and then of lung cancer chemotherapy and immunotherapy. Int. J. Mol. Sci 2017;18:1374.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics. Ca-Cancer J. Clin 2019;69:363–85.
   PubMed Web of Science ®Google Scholar
• Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China. Chin J Cancer Res 2018;30:1–12.
   PubMed Web of Science ®Google Scholar
• Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO classification. Front. Front Oncol 2017;7:193.
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non–small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clinic Proceedings 2019;94:1623–40.
   PubMed Web of Science ®Google Scholar
• Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824–32.
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350–6.
   PubMed Web of Science ®Google Scholar
• Yan G, Efferth T. Broad-spectrum cross-resistance to anticancer drugs mediated by epidermal growth factor receptor. Anticancer Res 2019;39:3585–93.
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res 2006;12:5268–72.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol 2006; 33:369–85.
   PubMed Web of Science ®Google Scholar
• Hynes NE, MacDonald GJ. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009;21:177–84.
   PubMed Web of Science ®Google Scholar
• Klapper LN, Kirschbaum MH, Seta M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res 1999;77:25–79.
   Web of Science ®Google Scholar
• Abdelkreem E, Mahmoud SM, Aboelez MO, Abd El Aal M. Abd El Aal M. Nebulized magnesium sulfate for treatment of persistent pulmonary hypertension of newborn: a pilot randomized controlled trial. Indian J Pediatr 2021;88:771–7.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127–37.
   PubMed Web of Science ®Google Scholar
• Heldin C-H. Dimerization of cell surface receptors in signal transduction. Cell J 1995;80:213–23.
   PubMed Web of Science ®Google Scholar
• Oh I-J, Ban H-J, Kim K-S, Kim Y-C. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer 2012;77:121–7.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 1987;26:1443–51.
   PubMed Web of Science ®Google Scholar
• Ghattas A-E-BA, Khodairy A, Moustafa HM, et al. Synthesis, in vitro antibacterial and in vivo anti-inflammatory activity of some new pyridines. Pharm Chem J 2017;51:652–60.
   Web of Science ®Google Scholar
• Press MF, Lenz H-J. Egfr, her2 and vegf pathways: validated targets for cancer treatment. Drugs 2007;67:2045–75.
   PubMedGoogle Scholar
• Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000;60:15–23. ‏
   PubMed Web of Science ®Google Scholar
• Gazdar A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28:S24–S31.
   PubMed Web of Science ®Google Scholar
• Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21–S6.
   PubMed Web of Science ®Google Scholar
• Clasadonte J, Sharif A, Baroncini M, Prevot V. Gliotransmission by prostaglandin E2: a prerequisite for GnRH neuronal function? Front. Endocrinol 2011;2:91.
   PubMedGoogle Scholar
• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505–16.
   PubMed Web of Science ®Google Scholar
• Zhang H, Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007;117:2051–8.
   PubMed Web of Science ®Google Scholar
• Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J. Cell. Physiol 2009;218:460–6.
   PubMed Web of Science ®Google Scholar
• Shahbazi S, Peer CJ, Polizzotto MN, et al. A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. J Pharm Biomed Anal 2014;92:63–8.
   PubMed Web of Science ®Google Scholar
• Zoppi V, Hughes SJ, Maniaci C, et al. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel–Lindau (VHL) based dual degrader probe of BRD9 and BRD7. J Med Chem 2019;62:699–726.
   PubMed Web of Science ®Google Scholar
• Shoman ME, Aboelez MO, Shaykhon MS, Ahmed SA, et al. New nicotinic acid-based 3,5-diphenylpyrazoles: design, synthesis and antihyperlipidemic activity with potential NPC1L1 inhibitory activity. Mol Divers 2021;25:673–86.
   PubMed Web of Science ®Google Scholar
• Qu X, Liu H, Song X, et al. Effective degradation of EGFRL858R + T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems. Eur J Med Chem 2021;218:113328.
   PubMed Web of Science ®Google Scholar
• Kumar J, Chawla G, Kumar U, Sahu K. Design and syntheses of some new quinoxaline derivatives containing pyrazoline residue as potential antimicrobial agents. Med Chem Res 2014;23:3929–40.
   Web of Science ®Google Scholar
• Aparaschivei R, Holban M, Sunel V, et al. Synthesis and characterization of new heterocyclic compounds with potential antituberculosis activity and their immobilization on polymer supports. Cellul Chem Technol 2012;46:301.
   Web of Science ®Google Scholar
• Tokgöz G, Demir Özkay Ü, Osmaniye D, et al. Synthesis of novel benzazole derivatives and evaluation of their antidepressant-like activities with possible underlying mechanisms. Molecules 2018;23:2881.
   PubMedGoogle Scholar
• Arief M, Aly A, Khalil A, Mohamed HI. Utility of 4-(isatin-3-ylideneamino) benzohydrazide in the synthesis of bioactive N-heterocyclic compounds. J Chem Pharm Res 2014;6:327–35.
   Google Scholar
• Farooq M, Almarhoon ZM, Taha NA, Baabbad AA, Al-Wadaan MA, et al. Synthesis of novel class of N-alkyl-isatin-3-iminobenzoic acid derivatives and their biological activity in zebrafish embryos and Human cancer cell lines. Biol Pharm Bull 2018;2018:b17-00674.
   Google Scholar
• Zhang C, Han X-R, Yang X, et al. Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK). Eur J Med Chem 2018;151:304–14.
   PubMed Web of Science ®Google Scholar
• An S, Fu L. Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs. EBioMedicine 2018;36:553–62.
   PubMed Web of Science ®Google Scholar
• Ogbole OO, Nkumah AO, Linus AU, Falade MO. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Mycology 1983;65:55–63.
   Google Scholar
• Thabrew MI, Hughes RD, McFarlane IG. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol 1997;49:1132–5.
   PubMed Web of Science ®Google Scholar
• Li P, Zhang Q, Torossian A, et al. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer. Int J Radiat Oncol Biol Phys 2012;83:e391–e7.
   PubMed Web of Science ®Google Scholar
• Huether A, Höpfner M, Baradari V, et al. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005;70:1568–78.
   PubMed Web of Science ®Google Scholar
• Van Schaeybroeck S, Kyula J, Kelly DM, et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 2006;5:1154–65.
   PubMed Web of Science ®Google Scholar
• Jia Y, Quinn CM, Gagnon AI, Talanian R. Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Anal Biochem 2006;356:273–81.
   PubMed Web of Science ®Google Scholar
• Wang J, Lenardo MJ. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J. Cell Sci 2000;113:753–7.
   PubMed Web of Science ®Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 1995;184:39–51.
   PubMed Web of Science ®Google Scholar
• Park JH, Liu Y, Lemmon MA, Radhakrishnan R. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J 2012;448:417–23.
   PubMed Web of Science ®Google Scholar
• Sogabe S, Kawakita Y, Igaki S, et al. Structure-based approach for the discovery of pyrrolo [3, 2-d] pyrimidine-based EGFR T790M/L858R mutant inhibitors. ACS Med Chem Lett 2013;4:201–5.
   PubMed Web of Science ®Google Scholar
• Moustafa AH, Ahmed WW, Awad MF, et al. Eco-friendly and regiospecific intramolecular cyclization reactions of cyano and carbonyl groups in N, N-disubstituted cyanamide. Mol. Divers 2022;2022:1–11.
   Google Scholar
• Meerloo JV, Kaspers GJ, Cloos J, Cell sensitivity assays: the MTT assay. In: Cancer cell culture. Totowa: Humana Press; 2011:237–45.
   Google Scholar
• Eldehna WM, Hassan GS, Al-Rashood ST, et al. Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J Enzyme Inhib Med Chem 2019;34:322–32.
   PubMed Web of Science ®Google Scholar
• Al-Rashood ST, Hamed AR, Hassan GS, et al. Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity. J Enzyme Inhib Med Chem 2020;35:831–9.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Nocentini A, Elsayed ZM, et al. Benzofuran-based carboxylic acids as carbonic anhydrase inhibitors and antiproliferative agents against breast cancer. ACS Med Chem Lett 2020;11:1022–7.
   PubMed Web of Science ®Google Scholar